Introduction
Cancer is the second leading cause of death in both developed and developing countries.
1,2 Chemotherapy has become one of the methods adopted to treat cancer. Many compounds have been synthesized with this aim, but their clinical use has been limited by their relatively high risk of toxicity, because they lack specificity and produce adverse effects related to the impact on rapidly dividing noncancerous cells. 2, 3 Therefore, to improve efficacy and decrease the adverse effect potential is one of the goals in developing new anticancer drugs. Another major goal for developing new anticancer agents is to overcome cancer resistance to drug treatment, which has made many of the currently available chemotherapeutic agents ineffective.
4
Novel 2-oxo-1,2-dihydropyridine-3-carbonitrile derivatives were reported as inhibitors of the oncogenic serine/threonine kinase PIM-1, which plays a role in cancer cell survival, differentiation, and proliferation ( Figure   1a ). 5 Moreover, several cyanopyridines with higher lipophilic properties ( Figure 1b) can inhibit survivin, which is a member of the inhibitors of apoptosis (IAP) family. 6 Survivin is highly expressed in most human tumors and fetal tissue but undetectable in most terminally differentiated adult tissues. This fact makes survivin an ideal target for cancer therapy. 7, 8 Milrinone (Figure 1c ) is a 3-cyanopyridine derivative that has been used for the treatment of congestive heart failure via PDE3 inhibition. Recent studies showed that PDE3, PDE4, and PDE5 are overexpressed in cancerous cells compared with in normal cells. In addition, inhibition of tumor cell growth and angiogenesis may be due to cross inhibition of PDE3 together with other PDEs. Pyridines are a class of both synthetically and naturally occurring heterocyclic compounds with a wide range of biological applications. 11−13 Moreover, the current interest in the development of new antimicrobial and anticancer agents can be partially ascribed to both the increasing emerging resistance among new pathogens and the appearance of multidrug resistance, and adverse side effects are a serious threat to public health. Therefore, the development of new and efficacious drugs is a very important goal, and most of the research efforts in this field are directed towards the design of new agents. 4, 14, 15 It is reported that some important anticancer drugs possess a pyridine nucleus. 16−18 Thus, this study gives promising compounds possessing a pyridine nucleus that can be investigated for future in vivo and clinically oriented studies. It is suggested that the linkage between alpha carbons of pyridine is important for cytotoxic effects regardless of 4-substituents. From the structureactivity relationships, it is revealed that the terpyridine skeleton is important for cytotoxicity against several human cancer cell lines, which supports the previous results.
19−21
Multicomponent reactions (MCRs) are powerful tools in modern medicinal chemistry because such reactions have constituted an increasingly valuable approach to drug discovery efforts in recent years.
22−24
In view of these observations and in continuation of our previous work, 25−34 we report herein the synthesis of some new derivatives of pyridines in MCRs and preliminarily evaluate their anticancer properties with the aim of obtaining better antimicrobial and anticancer drugs without side effects.
Results and discussion

Chemistry
The required 5-acetyl-2-mercapto-4-methyl-1-phenyl-1H -imidazole 1 was prepared according to the literature method. 35 A series of 3-cyanopyridine derivatives 4a-e were prepared by one-pot condensation of acetylimidazole 1, an aldehyde 2a-e, malononitrile 3, and ammonium acetate in refluxing acetic acid (Scheme 1). The structures of compounds 4a-e were confirmed by their spectral data. The IR spectra of compound 4a showed CN and NH 2 groups in their expected locations at v max = 2212, 3254, and 3431 cm −1 , respectively. The 1 H NMR of compound 4a showed a singlet (1H) at δ = 8.03 ppm attributable to pyridine H-5, along with the expected D 2 O exchangeable protons at δ =7.83 ppm assignable for NH 2 protons. Moreover, an EI mass spectroscopic technique gave its correct molecular ion peak at m/z = 383 (see Experimental section). The reaction goes in parallel to the literature.
36−38
In a similar manner, acetyl compound 1 was condensed with the appropriate aromatic aldehydes and ethyl cyanoacetate in the presence of excess ammonium acetate in acetic acid to give the corresponding cyanopyridones 6a-e in a one-pot reaction (Scheme 2). Scheme 2. Synthesis of pyridine derivatives 6a-e.
The structure of the isolated products was confirmed on the basis of their elemental analysis and spectral data. For example, taking compound 6a as a typical example, its IR spectrum exhibited absorption bands at v max = 1668, 2221, and 3431 cm −1 due to CO, CN, and NH groups, respectively. Its 1 H NMR spectrum showed singlet signals (D 2 O exchangeable) at δ = 11.32 ppm, due to NH proton, in addition to an aromatic multiplet in the region δ = 7.02-7.65 ppm, whereas the mass spectrum showed a peak corresponding to its molecular ion at m/z 384 (see Experimental section).
In addition, compound 1 was reacted with diethyl malonate, aldehyde, and ammonium acetate to give the corresponding ethyl 6-(imidazol-5-yl)-2-oxo-1,2-dihydropyridine-3-carboxylate derivatives 8a-e (Scheme 3) based on elemental and spectral data. IR spectra for compound 8a showed the stretching vibrations of 2CO and NH groups at 1667, 1725, and 3280 cm −1 , respectively. In addition, mass spectra of all derivatives displayed all correct molecular ion peaks. The 1 H NMR spectrum displayed characteristic signals at δ = 1.22(t), 4.26(q), and 11.96 ppm related to the ethyl group and NH protons, respectively (see Experimental section).
The mechanism of the one-pot synthesis of pyridine derivatives 4a-e, 6a-e, and 8a-e is known to be through the formation of α , β -unsaturated ketones intermediate via the Claisen-Schmidt reaction between the ketone and aromatic aldehydes. This reaction is followed by condensation with active methylene compounds (e.g., malononitrile or ethyl cyanoacetate or diethyl malonate) through the Michael addition reaction in the presence of ammonium acetate, cyclization, and aromatization to afford the corresponding pyridine derivatives 4a-e, 6a-e, and 8a-e (Scheme 4). We extended our protocol to the synthesis of bipyridine derivatives (10-12) via reacting 5-acetylimidazole 1 (1.0 mmol) with terephthaldehyde (0.5 mmol), malononitrile (or ethyl cyanoacetate or diethyl malonate) (1.0 mmol) under optimized conditions to give the corresponding bipyridine derivatives (10-12) (Scheme 5). Structure confirmation of compounds 10-12 was assisted by their analytical and spectral data. For instance, the IR spectrum of compound 10 displayed characteristic absorption bands at 3430 and 3140 cm −1 related to the NH 2 group as well as a cyano stretching vibration at 2211 cm −1 . Its 1 H NMR spectrum showed a singlet signal integrating for four protons (2NH 2 ) at 2.58 ppm, and a singlet signal at 7.82 ppm, which was assigned to the 5-H pyridine proton. The mass spectrum of 10 showed a peak in accordance with the proposed structure at m/z (%) = 688 (see Experimental section).
Scheme 5. Synthesis of bipyridine derivatives 10-12.
Biology
Antimicrobial activity
The in vitro antibacterial activity of the newly synthesized compounds was evaluated against two gram-positive bacteria, namely Staphylococcus pneumoniae (SP) and Bacillus subtilis (BS), and two gram-negative bacteria,
namely Pseudomonas aeruginosa (PA) and Escherichia coli (EC). They were also tested for their in vitro antifungal activity against three fungi species, namely Aspergillus fumigatus (AF), Geotrichum candidum (GC),
Candida albicans (CA), and Syncephalastrum racemosum (SR). The organisms were tested against the activity of solutions of concentration (5 µ g/mL) of each compound and using inhibition zone diameter (IZD) in mm as the criterion for antimicrobial activity (agar diffusion well method). The bactericides ampicillin and gentamicin and the fungicide amphotericin B were used as references to evaluate the potency of the tested compounds under the same conditions. The results are summarized in Tables 1 and 2 . They indicate the following:
1. Compounds 4c, 4d, and 8d exhibit high inhibitory effects against Staphylococcus pneumoniae, while compounds 4a, 4b, 4e, 8a, and 10 exhibit moderate inhibitory effects.
2. Compounds 4c, 6a, 6e, 8b, 8d, 10, 11, and 12 exhibit high inhibitory effects against Bacillus subtilis, while compounds 4a, 4b, 4e, 6b, and 8c exhibit moderate inhibitory effects and no inhibitory effect towards Pseudomonas aeruginosa.
3. Compounds 4c, 4d, 6a, 6e, 8d, and 12 exhibit high inhibitory effects against Escherichia coli.
4. Compounds 4c, 4d, 6a, 8d, 10, 11, and 12 exhibit high inhibitory activities against Aspergillus fumigatus, Syncephalastrum racemosum, and Geotrichum candidum, while compounds 4a and 8a have moderate inhibitory activity and all compounds have no activity against Candida albicans. 
Anticancer activity
The cytotoxicity of synthesized products 4b, 4c, 4d, 6b, 6d, 8b, 8c, 10, 11, and 12 was evaluated against human breast cell line (MCF-7) and liver carcinoma cell line (HEPG-2) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay Doxorubicin and vinblastine sulfate were used as reference drugs (IC 50 value of 0.42 ± 0.03 and 5.7 ± 0.60 µ g/mL against MCF-7 as well as 0.46 ± 0.04 and 4.6 ± 0.5 µ g/mL, against HepG2, respectively). Data generated were used to plot a dose response curve, from which the concentration of test compounds required to kill 50% of the cell population (IC 50 ) was determined. Cytotoxic activity was expressed as the mean IC 50 of three independent experiments. The results are represented in Tables 3-6 . They indicated that: Where Vinb-S and Dox were standard drugs vinblastine sulfate and doxorubicin, respectively Where Vinb-S and Dox were standard drugs vinblastine sulfate and doxorubicin, respectively. • The order of activity was 10 > 6d > 11 > 4d > 6b > 4c > 8c > 4b > 12 > 8b, which is in accordance with the order of breast carcinoma cells inhibitory activity (Table 4) .
• The order of activity was 6d > 11 > 4d > 10 > 4c > 6b > 8c > 4b > 12 > 8b, which is in accordance with the order of hepatocellular carcinoma cells inhibitory activity (Table 6 ).
Experimental section
General
Melting points were measured on Electrothermal IA 9000 series digital melting point apparatus. The IR spectra were recorded in potassium bromide discs on a Pye Unicam SP 3300 and Shimadzu FT IR 8101 PC infrared spectrophotometer. 1 H NMR and 13 C NMR spectra were recorded in deuterated dimethyl sulfoxide (DMSOd6) using a Varian Gemini 300 NMR spectrometer (300 MHz for 1 H NMR and 75 MHz for 13 C NMR). Mass spectra were recorded on a Shimadzu GCMS-QP1000 EX mass spectrometer at 70 eV. Elemental analysis was carried out at the Microanalytical Center of Cairo University, Giza, Egypt. All reactions were followed by TLC (silica gel, Merck). Antitumor activity was evaluated by the Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt.
General procedure for synthesis of pyridine derivatives 4a-e, 6a-e, and 8a-e
A mixture of 5-acetyl-2-mercapto-4-methyl-1-phenyl-1H -imidazole 1 (0.232 g, 1 mmol), malononitrile 3 or ethyl cyanoacetate 5 or diethylmalonate 7 (1 mmol), the appropriate aldehyde 2a-e (1 mmol), and ammonium acetate (0.616 g, 8 mmol) in glacial acetic acid (20 mL) was refluxed for 6-8 h (monitored by TLC). The mixture was cooled to room temperature and the precipitated products were separated by filtration, washed successively with water, dried, and crystallized from ethanol. The synthesized compounds together with their physical and spectral data are listed below. -4-methyl-1-phenyl-1H -imidazol-5-yl)-4-(4-methoxyphenyl)-2-oxo-1,2- 
2-Amino-6-(2-mercapto-4-methyl-1-phenyl-1H -imidazol-5-yl)-4-phenylnicotinonitrile (4a).
2-Amino-4-(4-chlorophenyl)-6-(2-mercapto-4-methyl-1-phenyl-1H -imidazol-5-yl)nicotinonitrile (4b
2-Amino-6-(2-mercapto-4-methyl-1-phenyl-1H -imidazol-5-yl)-4-(4-methoxyphenyl) nicotinonitrile (4c
2-Amino-4-(2-hydroxyphenyl)-6-(2-mercapto-4-methyl-1-phenyl-1H -imidazol-5-yl)nicotinonitrile (4d
2-Amino-4-(2,4-dimethylphenyl)-6-(2-mercapto-4-methyl-1-phenyl-1H -imidazol-5-yl)nicotinonitrile (4e
6-(2-Mercapto-4-methyl-1-phenyl-1H -imidazol-5-yl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile (6a
4-(4-Chlorophenyl)-6-(2-mercapto-4-methyl-1-phenyl-1H -imidazol-5-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (6b
6-(2-Mercapto
General procedure for synthesis of bipyridine derivatives 10-12
A mixture of 5-acetylimidazole 1 (0.464 g, 2 mmol), malononitrile 3 or ethyl cyanoacetate 5 or diethyl malonate 7 (2 mmol), the terephthalaldehyde 9 (0.134 g, 1 mmol), and ammonium acetate (1.232 g, 16 mmol) in acetic acid (30 mL) was refluxed for 6-8 h (monitored by TLC). The reaction mixture was cooled and poured into cold water; the resulting precipitate was filtered off, washed with water, and recrystallized from dioxane to give the corresponding bipyridine products 10-12. The synthesized compounds together with their physical and spectral data are listed below. 
Biological part
Antimicrobial activity test
Agar diffusion is the method adopted for such tests. The microorganism inocula were uniformly spread using a sterile cotton swab on a sterile petri dish of malt extract agar (for fungi) and nutrient agar (for bacteria).
Then 100 µ L of each sample was added to each well (10 mm diameter holes cut in the agar gel, 20 mm apart from one another). The systems were incubated for 24-48 h at 37
• C (for bacteria) and at 28
• C (for fungi).
After incubation, the microorganism's growth was observed. Inhibition of the bacterial and fungal growth was measured as IZD in mm. The tests were performed in triplicate. 
Cytotoxic activity
The method of Skehan et al. 40 was used for potential cytotoxicity measurements of the synthesized compounds using Sulfo-Rhodamine-B (SRB) stain. Cells were plated in 96-multiwell plates (10 4 cells/well) for 24 h before treatment with the tested compound to allow attachment of cells to the wall of the plate. Next, 0, 1.56, 3.125, 6.25, 12.5, 25, and 50 µ g/mL of the testing compound were added to the cell monolayer in triplicate wells individual dose, and monolayer cells were incubated with the compounds for 48 h at 37
• C and in atmosphere of 5% CO 2 . After 48 h, the cells were fixed, washed, and stained with SRB stain. Excess stain was washed with acetic acid and attached stain was recovered with tris-EDTA buffer. Color intensity was measured using an ELISA reader. The relation between surviving fraction and drug concentration was plotted. The response parameter calculated was the IC 50 value, which corresponds to the compound concentration causing 50% mortality in net cells.
Conclusions
